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considering the endogenous metabolites as static variables 
but to include also drug dose and temporal changes in drug 
concentration in these studies. Although there are many 
endogenous metabolite biomarkers identified to predict PK 
and more often to predict PD, validation of these biomark-
ers in terms of specificity, sensitivity, reproducibility and 
clinical relevance is highly important. Furthermore, the 
application of these identified biomarkers in routine clinical 
practice deserves notable attention to truly personalize drug 
treatment in the near future.
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1 Introduction
One of the main challenges in modern drug therapy is 
that a single compound with one fixed dose does not opti-
mally treat all individuals in a population that suffer from 
a specific disease in a population. Knowledge about inter-
individual differences in drug pharmacology and descrip-
tors of these differences is essential to treat all individuals 
in a population effectively and safely. Individual variations 
in the response to drug treatment may result from genetic 
polymorphisms (Weinshilboum 2003) or other epigenetic 
factors, environmental factors including diet, life style, ear-
lier/current drug treatments, and microbiome (Li and Jia 
2013). Furthermore, demographic characteristics like age, 
sex, and bodyweight, or disease related factors like disease 
status and treatment-related factors (Alomar 2014) may 
cause variation. It is not known a priori which of these fac-
tors will best predict the clinical outcome of a treatment in 
an individual.
Abstract Personalized medicine, in modern drug ther-
apy, aims at a tailored drug treatment accounting for 
inter-individual variations in drug pharmacology to treat 
individuals effectively and safely. The inter-individual 
variability in drug response upon drug administration is 
caused by the interplay between drug pharmacology and 
the patients’ (patho)physiological status. Individual varia-
tions in (patho)physiological status may result from genetic 
polymorphisms, environmental factors (including current/
past treatments), demographic characteristics, and disease 
related factors. Identification and quantification of predic-
tors of inter-individual variability in drug pharmacology 
is necessary to achieve personalized medicine. Here, we 
highlight the potential of pharmacometabolomics in pro-
spectively informing on the inter-individual differences in 
drug pharmacology, including both pharmacokinetic (PK) 
and pharmacodynamic (PD) processes, and thereby guid-
ing drug selection and drug dosing. This review focusses 
on the pharmacometabolomics studies that have additional 
value on top of the conventional covariates in predicting 
drug PK. Additionally, employing pharmacometabolomics 
to predict drug PD is highlighted, and we suggest not only 
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Personalized medicine, also sometimes referred to as 
precision medicine, aims to offer a tailored drug treatment 
to achieve the most optimal therapeutic effects with the 
least amount of adverse effects for each individual (Schork 
2015). Information provided by predictors of expected indi-
vidual responses to a particular drug, can inform clinicians 
in the decision making process for drug selection and drug 
dosing regimen (Kitsios and Kent 2012). And we are con-
vinced that pharmacometabolomics will allow to find meta-
bolic predictors for drug selection and drug dosing as will 
be elaborated in this paper.
2  Interplay between drug pharmacology 
and patients’ (patho)physiology
For optimal pharmacotherapy, the interplay between drug 
pharmacology and patients’ (patho)physiology needs to 
be understood (van der Greef and McBurney 2005; Vicini 
and van der Graaf 2013). As illustrated in Fig.  1, impor-
tant aspects regarding drug pharmacology are target expo-
sure, target binding, and target activation, these processes 
are governed by drug-specific properties and patient char-
acteristics. Modulating (patho)physiological biochemis-
try networks on a cellular level and, more importantly, on 
a tissue or organ level, or systemic level, will eventually 
determine the treatment outcome for a patient. The target 
activation triggers modulation of the (patho)physiologi-
cal system including self-regulatory feedback mechanisms 
of the patient, also called downstream effects, and these 
modulations can vary between patients. When studying the 
effects of pharmacotherapy, none of the processes in the 
chain from drug administration to patient outcome (Fig. 1) 
should be studied in isolation. Rather, all aspects need to be 
considered in the context of their causal and temporal inter-
actions. Moreover, in order to achieve truly personalized 
medicine, inter-individual variability throughout these pro-
cesses need to be quantified and predictors for inter-indi-
vidual difference identified.
Biomarkers are important tools to study the complex 
interplay between drug pharmacology and the patients’ 
(patho)physiology, both on a population level and on an 
individual level. In this context, biomarkers are “a measure 
that characterizes, in a strictly quantitative manner, a pro-
cess, which is on the causal path between drug administra-
tion and effect” (Danhof et al. 2005). A variety of biomark-
ers currently exist and endogenous metabolites, or more 
probably metabolite fingerprints (Adourian et al. 2008; van 
der Greef and McBurney 2005), are promising for provid-
ing novel biomarkers for all processes on the causal chain 
between drug dose and patient outcome as outlined in 
Fig. 1.
If a drug does not reach its target, it cannot elicit its 
effect. Thus, drug concentration in blood is a biomarker 
for target exposure. Because drug concentrations at the tar-
get site may be difficult to measure, drug concentration in 
plasma is often used as a convenient surrogate measure for 
target exposure. However, in some cases where a compound 
has a peripheral target site (e.g. in brain), drug concentra-
tions in blood cannot fully predict the target exposure.
Pharmacokinetics (PK) is the study of drug absorp-
tion, distribution, metabolism and excretion. Pharmacoki-
netic profiles describe the time course of drug concentra-
tions in plasma or other tissues or biological matrices. 
Total drug exposure in a certain tissue is represented by 
the area under the concentration curve (AUC). The pro-
cesses underlying drug PK are quantified using primary 
parameters like clearance (CL) and distribution volume 
(V), or secondary parameters like absorption or distribu-
tion rate constants. Inter-individual variability in biologi-
cal processes results in variability in the drug PK profiles 
between individuals. The ability to predict individual 
Fig. 1  Potential of metabo-
lomics in the interplay between 
drug pharmacology and patients 
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variations in the PK of drugs prior to drug administration 
is of interest in order to avoid over-dosing (e.g. adverse 
effects) and under-dosing (e.g. therapeutic failure). Cur-
rently, demographic, disease-related or treatment-related 
factors including for instance age, bodyweight, disease 
state, drug formulation, and concomitant drug therapy, 
are used as predictors of quantitative inter-individual dif-
ferences in the PK of drugs. These predictive factors of 
variability are called covariates.
Current methodologies using conventional covariates 
alone can often explain a large part of the inter-individual 
variability in the PK of a drug (Joerger 2012). However, 
this may not be sufficient for drugs with a narrow therapeu-
tic window and relatively high unexplained inter-individual 
variability. In these cases, therapeutic drug monitoring 
(TDM) provides a viable option to improve an individu-
als’ pharmacotherapy. With TDM, dose adjustments are 
made based on additional information on the individual PK 
parameter values, derived from relevant exposure measures 
after one or multiple drug doses have been administered.
There are, however, situations where the use of conven-
tional covariates, even in combination with TDM, is not 
sufficient to guide drug dosing for target exposure attain-
ment. In critically-ill patients, patients with organ failure, or 
in the end-of-life stages of terminal patients, many (patho)
physiological changes and drug–drug interactions occur in 
quick succession, and all or a number of these factors may 
influence the PK of administered drugs. In these vulnerable 
patients, the exact clinical status is difficult to assess using 
conventional measures, but this information may be essen-
tial to predict the individual PK parameter values needed to 
provide personalized drug dosing.
To elicit an effect, a drug should not just reach a tar-
get, it should also bind to the target and activate the target 
to initiate the desired biosignal that will for instance lead 
to changes in enzyme activity or changes a (patho)physi-
ological pathway. Factors that influence these interactions 
include both the physicochemical properties of the drug 
and the phenotype of the patient. Inter-individual differ-
ences in the target phenotype may influence target binding 
and activation and thereby the eventual treatment outcome 
in individual patients.
The biosignal initiated by target activation is subse-
quently potentiated into the (patho)physiological system 
of the patient. Potentiation of this signal may involve rela-
tively simple molecular pathways, but often involves com-
plex interacting networks related both to healthy physiol-
ogy and disease-related pathophysiology, that will yield 
modulations on cellular, tissue and organ levels, and on the 
disease state level. A wide range of these factors related 
to (epi)genetic factors and patient phenotype may result 
in inter-individual variability in signal potentiation and 
thereby patient outcome.
Drug pharmacodynamics (PD) is related to the effect of 
drugs and in PK-PD analysis the relationship between drug 
concentration, usually in blood, and treatment outcome is 
defined. Usually, inter-individual variability in PD pro-
cesses exceeds the inter-individual variability in PK. Fail-
ure to properly account for the variability in the PD of a 
drug may cause therapy failure or toxicity for individual 
patients (Levy 1998).
As indicated in Fig.  1, drug effects, either desired or 
unwanted side-effects, can be described on different levels 
(from target exposure, to target binding and target activa-
tion, to ultimately disease modulation leading to clinical 
outcome) and the relationships between drug concentra-
tion and effect will become less direct and potentially more 
complex when moving downstream in signal potentiation, 
and ultimately to clinical outcome. Especially in complex 
diseases of which the mechanism is not yet fully under-
stood, for instance psychological and neurological diseases, 
there is a strong need for validated biomarkers to assess 
disease progression. In addition, such a biomarker can be 
informative about the impact of pharmacotherapy on vari-
ous levels of the (patho)physiological system.
Similar to PK, conventional covariates can be used as 
predictors for inter-individual variability in drug effects, 
but, similar to TDM, in PD they may not always be suf-
ficient. Moreover, also similar to TDM, dose adjustments 
and even drug selection should be guided based on predic-
tion of individual patient outcome, particularly for drugs in 
which the drug effects are difficult to quantify or delayed 
(e.g. psychoactive drugs, cytostatics, antidepressants, etc.). 
Another example where we need proper PD prediction is 
the use of drugs in vulnerable or critical patients. In these 
cases, validated biomarkers that can predict long-term out-
come based on short-term changes are needed to facilitate 
individual optimization of pharmacotherapy.
As outlined above, optimal pharmacotherapy requires 
information on the current (patho)physiological status of 
an individual patient. Conventional covariates may be use-
ful in this respect and may even be sufficient in predicting 
individual deviations from population responses, but when 
these don’t suffice, other methods for the establishment of 
phenotypic profiles may be required. Such methods are 
preferably prospective and minimally invasive.
One way of PK phenotyping involves the administra-
tion of a probe drug or drug cocktail to assess the pheno-
type of several drug-metabolizing enzymes (Sharma et al. 
2004). However, this is not always feasible, especially in 
vulnerable populations, and this involves prolonged clinical 
visits and increases time and cost of treatment. An alter-
native phenotyping approach would be using endogenous 
biomarkers that could predict enzyme activity without risk, 
time, and cost of exogenous drug administration. Another 
advantage of endogenous biomarkers is that retrospective 
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analysis of banked samples can be conducted. Identified 
predictive endogenous biomarkers can be used as covariates 
to guide clinicians in decision making regarding treatment 
options by using minimal amounts of biological fluids. In 
this regard, the application of metabolomics can serve as an 
alternative or additional method to the current clinical prac-
tices to achieve personalized treatment (Bernini et al. 2009; 
Fernie et  al. 2004; Guo et  al. 2015; Schnackenberg 2007; 
Suhre et al. 2011; van der Greef et al. 2006).
Metabolomics or endogenous metabolite profiling may 
be used as a phenotypic tool to provide accurate informa-
tion on the current (patho)physiological status of patients 
to prospectively inform on individual differences in both 
PK and PD processes and thereby guide drug selection and 
drug dosing. Furthermore, in cases where the exact mecha-
nism of a disease or drug effect is unknown, endogenous 
metabolites and their change after administration of a drug 
can provide mechanistic insight in disease status and drug 
response of an individual (Kaddurah-Daouk et al. 2008).
3  Metabolomics and pharmacometabolomics
Pharmacogenomics (PG), which uses genetic polymor-
phisms to predict individual variations in responses to 
drugs, for instance to classify patients as poor or rapid drug 
metabolizers, or drug responders or non-responders (Evans 
and McLeod 2003; Evans and Relling 2004; Pirmohamed 
2014) has been increasingly used to inform personalized 
medicine. However, studying a patient’s genotype does not 
always allow for a clear definition of a phenotype, nor does 
it give information about the current (patho)physiologi-
cal state of an individual (Carr et  al. 2014), as the geno-
type does not capture time-varying processes influenced by 
environmental factors and/or disease-related factors.
Metabolomics offers an advantage over PG in explaining 
the inter-individual variability in drug PK or PD, as it pro-
vides a direct readout of the current metabolic state of an 
individual. The endogenous metabolite profile is a snapshot 
of the phenotypic status of an individual resulting from, for 
instance, demographic factors, environmental interactions, 
microbiota, or disease status. Pharmacometabolomics is 
emerging as a discipline of metabolomics that studies the 
interplay between drug pharmacology and the patients’ 
(patho)physiology, by measuring endogenous metabolites 
that inform on variability in the drug PK or PD phenotype 
(Clayton et al. 2006; Kaddurah-Daouk and Weinshilboum 
2015; Lindon et al. 2006; Nicholson et al. 2011). This con-
cept has first been illustrated in rats, in a study that showed 
that metabolomic information in pre-dose urine samples is 
predictive of both drug metabolism (PK) and toxicity (PD) 
of paracetamol (Clayton et al. 2006).
So far, pharmacometabolomic research addresses:
1. The identification of endogenous metabolites for pre-
dicting individual drug PK characteristics (Huang et al. 
2015; Kienana et  al. 2016; Phapale et  al. 2010; Rah-
mioglu et  al. 2011; Shin et  al. 2013; Tay-Sontheimer 
et al. 2014).
2. The identification of endogenous metabolites and their 
metabolic pathways for predicting individual drug PD 
characteristics (Condray et al. 2011; Kaddurah-Daouk 
et  al. 2010, 2011a, b; Kaddurah-Daouk and Wein-
shilboum 2014; Keun et  al. 2009; Krauss et  al. 2013; 
Trupp et al. 2012; Yerges-Armstrong et al. 2013; Zhu 
et al. 2013).
3. The identification of endogenous metabolite biomark-
ers for monitoring disease progression and pharmaco-
therapy in individual patients (Backshall et  al. 2011; 
Kinross et al. 2011; Nicholson et al. 2012).
The analytical methods applied to discover metabolic 
biomarkers use advanced and sensitive analytical instru-
ments such as NMR, LC-MS and GC-MS (Chen et  al. 
2007; Dona et al. 2014; Emwas et al. 2013; Garcia and Bar-
bas 2011). Metabolomics research can be conducted either 
in a targeted or un-targeted fashion. In targeted approaches, 
pre-selected endogenous metabolites, which belong either 
to defined chemical classes or to particular metabolic path-
ways, are quantified. In an untargeted approach or a global 
profiling approach, endogenous metabolites are quanti-
fied in an unbiased fashion without any pre-selection of 
metabolites. This mode is advantageous in exploratory 
studies, which can generate hypotheses as well as gener-
ate data for biomarker discovery. However, in an untargeted 
metabolomic analysis, the physicochemical properties of 
the metabolites determine whether they can be in princi-
ple extracted and detected, and quantitative information on 
endogenous metabolite concentration is often less precise 
than in targeted analysis, and comparability between stud-
ies and labs is less straightforward than in targeted analy-
sis, where absolute concentrations are reported for targeted 
metabolites for which a calibration model is available.
For the discovery of metabolite biomarkers to identify 
predictors of PK and/or PD variability or for monitoring 
the disease progression and the modulation of the disease 
progression by pharmacotherapy, disease metabolic pheno-
types or pre- and post-dose metabolic phenotypes are often 
established. These metabolic phenotypes offer unique read-
outs that contain information about the (patho)physiologi-
cal state of an individual at particular time points. The opti-
mal design of the metabolomic biomarker discovery study, 
will depend on the intended use of the biomarker, which 
could include for instance identification of responders and 
non-responders to drug treatment, predict individual PK 
variability or assess drug–drug interactions. The statistical 
models of the metabolomics data will then integrate both 
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causal and temporal information. Ultimately, the metabolite 
biomarkers may be used in routine clinical practice, either 
prospectively to guide drug selection and drug dose selec-
tion based on pre-dose metabolite biomarker profiles, or 
retrospectively to monitor the effects of pharmacotherapy.
Figure 2 illustrates the use of pharmacometabolomics 
in both research (route A) and clinical practice (route 
B). Route A illustrates how pharmacometabolomics can 
be coupled to the clinical outcome variables of phar-
macotherapy to investigate and identify metabolomic 
biomarkers for drug pharmacology and the interac-
tion with patients’ (patho)physiology. In this route, pre-
dose and post-dose endogenous metabolite profiles are 
obtained together with individual PK and PD variables. 
Using a range of multivariate statistical methods such as 
for instance principal component analysis (PCA), par-
tial least squares discriminant analysis (PLS-DA) and 
orthogonal partial least squares discriminant analysis 
(O-PLS-DA), correlations between endogenous metabo-
lites and pharmacological characteristics can be inves-
tigated (Bartel et  al. 2013). Further research is then 
focused on identifying the role of the biomarker in the 
causal chain between drug administration and patient out-
come, for instance using network analysis (Kotze et  al. 
2013) and/or population models that quantify the time 
course of drug concentration and drug effect (Gabriels-
son et  al. 2011; Wright et  al. 2011). Route B illustrates 
how the pharmacometabolomic information obtained in 
route A is prospectively applied in clinical practice to 
personalize drug treatment. Using pre-dose samples and 
the quantitative knowledge on the relationships between 
endogenous metabolites and pharmacological outcome, 
pharmacotherapy, in terms of drug selection and dose 
selection, can be tailored to an individual.
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Fig. 2  Pharmacometabolomics in research (route A) and clinical 
practice (route B). Route A (red) discovery of metabolite biomarkers 
to predict pharmacological treatment outcome using statistical meth-
ods that couple data from metabolomics profiling to PK and / or PD 
variables of an individual. Route B (blue) prospective application of 
metabolite biomarkers in routine clinical practice, using information 
from route A for personalized treatment
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4  Pharmacometabolomics informs 
pharmacokinetics
Target exposure is one of the first steps on the causal chain 
linking drug dosing to patient outcome. Knowledge on the 
sources and extent of inter-individual variability and the 
availability of descriptors for variability, will allow cli-
nicians to prospectively adjust drug doses for individual 
patients.
The main aim of pharmacometabolomic studies related 
to drug PK is to identify endogenous metabolite markers 
that allow for the stratification of patients into exposure 
groups, which is needed to individualize drug dosing regi-
mens. Factors that are known to have marked impact on the 
PK of drugs include, for instance, expression and activity 
of drug metabolizing enzymes, tissue composition includ-
ing the expression of drug binding plasma proteins and tis-
sue proteins, drug transporters, and gut microbiome.
One of the first reported human studies linking pre-dose 
metabolomics information in urine to drug exposure meas-
ures was performed in healthy volunteers taking tacrolimus 
(Phapale et  al. 2010). Tacrolimus is an immunosuppres-
sant used during organ transplantation and has a narrow 
therapeutic index with a high degree of inter-individual 
variability in its PK. As dose adjustments of this drug are 
futile by the time over-dosing (e.g. organ toxicity) or under-
dosing (e.g. organ rejection) become apparent, accurate 
exposure monitoring or prediction is important. In the 
study, the authors used first untargeted metabolomic pro-
filing and multivariate statistics to correlate endogenous 
urine metabolites to the AUC of tacrolimus. Then a hypo-
thetical molecular network was developed that included 
the obtained metabolic biomarkers, and findings on impor-
tant modules in this network were linked to mechanistic 
knowledge of the underlying PK processes for tacrolimus 
to select possibly causal biomarkers. From this, a metabo-
lomic phenotype based on pre-dose urine concentrations of 
four endogenous metabolites was derived that can predict 
a patients’ exposure to tacrolimus, thereby allowing a pro-
spective individual dose selection.
Another report linked pre-dose plasma metabolomic 
profiles to exposure measures of atorvastatin in healthy vol-
unteers (Huang et al. 2015). Atorvastatin is an HMG-CoA 
reductase inhibitor for which considerable inter-individual 
variability in drug metabolism leads to up to 45-fold differ-
ences in plasma concentrations leading to therapy failure in 
some and adverse effects in others. In this study, the authors 
first applied untargeted profiling of metabolites with 
GC-MS and PLS analysis to establish a model that predicts 
endogenous metabolites and pharmacokinetic parameters 
(Cmax and AUC). Using selected metabolites, hypothetical 
metabolic networks were constructed to visualize the role 
of metabolite pathways explaining the variability. Later, 
an O-PLS model was used to stratify the individuals into 
subgroups based on the pre-dose metabolite behavior. For 
atorvastatin conventional covariates have proven to be sub-
optimal in predicting individual exposure measures and this 
study showed a combination of endogenous metabolite bio-
markers to have increased predictive value for this drug.
As drug metabolizing enzyme activity is an impor-
tant contributor to drug clearance, and as drug clearance 
is a major determinant for exposure, some (pharmaco)
metabolomic studies investigate endogenous metabolomic 
predictors for drug metabolizing enzyme activity in gen-
eral. It is, however, important to note that other factors, 
including hepatic blood flow, plasma protein binding, and 
hepatic transporters, also influence drug metabolic clear-
ance. These factors may limit the direct translation of find-
ings regarding drug metabolism of one probe compound to 
other compounds that are substrates for the same enzymes.
When focusing on the metabolism, CYP3A enzymes 
are responsible for the metabolism of the majority of pre-
scribed drugs. These enzymes have multiple functional 
alleles and they are subject to induction and inhibition by 
various exogenous compounds. The interaction processes 
are highly variable between individuals and become espe-
cially relevant in patients taking multiple drugs. To inves-
tigate the applicability of pharmacometabolomics in pro-
spectively informing on induction of CYP3A4 metabolism, 
Rahmioglu et  al. performed a study correlating pre-dose 
metabolomic urine measures to quinidine metabolite ratios 
after CYP3A4 induction with Hypericum perforatum, 
known as St. John’s Wort (Rahmioglu et al. 2011). Endoge-
nous urinary metabolite measures were identified that were 
predictive of the quinidine metabolite ratio [3-hydroxyqui-
nine to quinine (3OH-Q:Q)], but they all remained empiri-
cal predictors as none of these could be mechanistically 
linked to CYP3A4 activity. A potential explanation for this 
is that ratios in drug metabolite concentrations are depend-
ent on both formation and elimination rates of metabolites, 
making this measure not very specific for enzyme activity 
alone.
A more recent study in healthy male volunteers used 
a more direct measure for CYP3A activity by investigat-
ing the clearance of midazolam, a drug that is known 
to be predominantly cleared through CYP3A-mediated 
metabolism. Moreover, this study not only investigated 
scenarios after CYP3A induction using ketoconazole, 
but also included situations without drug interactions 
or with inhibition using rifampicin (Shin et  al. 2013). 
The authors were able to identify an endogenous ster-
oid metabolomic profile in urine which could accurately 
predict midazolam clearance under all investigated con-
ditions. A link between steroid metabolism and CYP3A 
activity had already been established, but this study 
defined a more predictive biomarker profile. Moreover, 
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the authors showed that timing of urine collection in each 
treatment phase did not influence the predictive value of 
the biomarker, suggesting that it can be reliably used to 
establish current midazolam clearance in patients that are 
already receiving drug therapy.
In the paediatric population, on top of genetic, envi-
ronmental and disease-related factors that are also present 
in adults, growth and development results in continuous 
changes in physiological processes underlying drug PK 
and PD. Much research efforts have focused on quantifying 
the influence of these changes on the PK, and to a lesser 
extent PD, of drugs in children. A recent study by Tay-
Sontheimer et al. (Tay-Sontheimer et al. 2014), illustrated 
a first attempt to use pharmacometabolomic approaches to 
prospectively and non-invasively predict drug clearance of 
a CYP2D6 substrate in this population as well. Strong con-
clusions cannot yet be made based on this study, since par-
ent and drug metabolite ratios were used to define enzyme 
activity. Other limitation in this study were encountered 
as the identified endogenous metabolite biomarker Ml, 
could not be structurally identified based on its fragmenta-
tion spectra, and most importantly the concentration of the 
endogenous metabolite biomarker was below the detection 
limits in samples of poor metabolizers. However, the idea 
of using pre-dose pharmacometabolomic measures to pro-
spectively determine drug doses in the pediatric population 
is appealing.
As most drug metabolism occurs in the hepatocytes of 
the liver, influx and efflux transporters in these cells may 
influence the metabolic clearance of their substrates. More-
over, efflux transporters in hepatocytes may offer an alter-
native clearance route by transporting drugs directly into 
the bile. Also within nephrons of the kidneys, active trans-
porters may facilitate drug excretion or reuptake. Finally, 
intestinal drug uptake and tissue distribution of drugs may 
be influenced by transporters. As with enzymes, genetic 
polymorphisms in drug transporters may influence their 
activity (Kerb 2006) and interactions with endogenous or 
exogenous compounds may induce or inhibit the transport-
ers in a time-dependent manner (Konig et al. 2013).
In a recent study using an untargeted metabolomics 
approach, a pre-dose urinary metabolomic profile based on 
28 endogenous metabolites was identified that was predic-
tive of the clearance of high-dose methotrexate in patients 
with lymphoid malignancies (Kienana et  al. 2016). Inter-
individual and inter-occasion variability in the clearance of 
methotrexate is large, leading to regular toxicity events in 
patients. Many of the 28 identified endogenous metabolites 
are substrates for organic anion transporters in the kidney, 
transporters that are also known to play a major role in the 
elimination of methotrexate, suggesting that metabolomic 
profiles may also provide information on the function of 
transporters at a given time-point.
Recently it has been recognized that the human gut 
microbiome may contribute to variations in the response 
to drug treatment, for instance by the bacterial synthesis 
of unique metabolites from administered drugs or their 
metabolites. In a study of paracetamol, Clayton et al., dem-
onstrated that formation of p-cresol by the gut microbiome 
results in a competitive interaction for the systemic sulpha-
tion of paracetamol, causing a decreased relative sulphation 
of the drug (Clayton et al. 2009). Given that the therapeu-
tic window of paracetamol is wide, this finding may not 
be of big relevance for this specific drug, but it may have 
important implications for other drugs that have a narrow 
therapeutic window and large inter-individual differences 
in drug metabolism. Also for simvastatin, a relationship 
between pre-dose levels of secondary bile acids produced 
in the gut and drug effect has been identified (Kaddurah-
Daouk et  al. 2011a, b), although the exact mechanism 
underlying this finding is not yet known. The identified sec-
ondary bile acids correlated with the concentration of sim-
vastatin, and interactions of these bile acids with (patho)
physiological mechanisms are also proposed to influence 
patients’ responses to simvastatin treatment. As the micro-
biome of individuals may vary over time, the results of 
these studies suggest that pharmacometabolomics may pro-
vide relevant information on the status of the microbiome 
of a patient at a given time and the expected effect this has 
on pharmacotherapy.
5  Pharmacometabolomics informs 
pharmacodynamics
The majority of pharmacometabolomic studies are focused 
on drug PD and changes in (patho)physiology upon drug 
exposure. The potential of this type of pharmacometabo-
lomic research has been highlighted for instance in neu-
ropsychiatric diseases (Kaddurah-Daouk et al. 2007, 2011a, 
b, 2013; Quinones and Kaddurah-Daouk 2009; Yao et  al. 
2010; Zhu et al. 2013), neurodegenerative disorders (Kad-
durah-Daouk et al. 2013), cardiovascular diseases (Kaddu-
rah-Daouk et al. 2010, 2011a, b; Krauss et al. 2013; Trupp 
et  al. 2012), cancer (Backshall et  al. 2011; Dang et  al. 
2009; Keun et al. 2009), chronic kidney disease (Zhao et al. 
2014) and hematology (Ellero-Simatos et al. 2014; Yerges-
Armstrong et al. 2013).
Most pharmacometabolomic studies in PD set out to 
investigate the effects of pharmacotherapy by investigating 
differences in pre and post-dose endogenous metabolomic 
profiles and identifying patterns that can explain inter-
individual differences in treatment outcome. However, as is 
illustrated in Fig. 1, changes in various levels of the (patho)
physiological system induced by pharmacotherapy should 
not be regarded as static or be studied in isolation, as they 
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only form one link in the context of their causal and tempo-
ral interaction in all the processes between drug adminis-
tration and patient outcome. The studies establishing a link 
between a specific endogenous metabolite or metabolite 
profile and treatment outcome of pharmacotherapy should 
therefore be followed up by extensive studies into the 
behavior of the new metabolite biomarker under various 
pharmacological interventions of the (patho)physiological 
system to validate the specificity, sensitivity, reproducibil-
ity, and clinical relevance of the new metabolite biomarker. 
These validation studies should focus on the influence of 
different drug doses or drug concentrations on the newly 
identified metabolite biomarker to establish a concentra-
tion-effect relationship, on understanding the causal and 
temporal relationships of changes in the new metabolite 
biomarker and other biomarkers or measurements of treat-
ment outcome, and on the response of the new metabo-
lite biomarker to pharmacotherapy with both agonist and 
antagonist agents. Population modeling approaches can 
provide a useful tool in quantitatively integrating all the 
information obtained in the various investigations.
6  Pharmacometabolomics informs the clinician
Although metabolomics studies have identified a number of 
metabolite biomarkers that can describe and predict inter-
individual variability in the PK or PD of drugs, the applica-
tion of the obtained knowledge in clinical practice remain 
relatively limited. Validation of promising metabolite bio-
markers is therefore urgently required to prove their speci-
ficity, sensitivity, reproducibility and clinical relevance. 
Once the understanding of causal and temporal relation-
ships and inter-individual variability is there, the obtained 
knowledge needs to be taken to the clinic to optimize drug 
therapy.
It is worth to mention that pharmacogenomics studies 
have played an important role in predicting drug PK in the 
last decade, but pharmacogenomics does not provide infor-
mation about the current (patho)physiological state of an 
individual, and take environmental factors into account. As 
one’s individual genome will be soon available for many 
persons, pharmacogenomics is very attractive for PK pre-
diction. However, there are many cases where pharmacog-
enomics was not able to predict PK, and where pharmaco-
metabolomics is an attractive alternative. The reason is that 
pharmacometabolomics provides a snapshot of the pheno-
typic status of an individual resulting from, for instance, 
demographic factors, environmental interactions, micro-
biota, or disease(s) status. We anticipate that pharmacome-
tabolomics and pharmacogenomics are very complemen-
tary techniques, which we expect will be often combined 
ultimately in clinical decision support for PK (and PD) 
prediction.
For the implementation of metabolic biomarkers in the 
clinical lab there are different requirements: (1) metabo-
lites should be reported as absolute concentrations, (2) the 
analysis should be cost-effective and (3) results should be 
available to the clinicians in a timely manner. Implementa-
tion can occur in two different ways, via targeted analysis, 
specific cost-efficient assays covering only a limited num-
ber of required metabolites, or a broader panel allowing for 
a general metabolomics assay covering hundred or more 
(identified) metabolites that inform about the general health 
state including the prediction of treatment outcome. For the 
targeted assay, we can expect that small analyzers will be 
developed. This might be based on aptamers, miniaturized 
NMR or mass spectrometers, and might be even handheld. 
For the broader clinical metabolic profile most probably a 
lab-based metabolite analyzer using a cost-efficient mass 
spectrometer will be used. The more metabolite biomark-
ers will become validated, the more attractive it will be 
to implement metabolite profiling in the clinical lab for 
clinical decision support, and we are convinced that with 
the significant increase of metabolomics studies reporting 
metabolic biomarkers for PK/PD this will become routine 
over some years.
It is worth mentioning that pharmacometabolomics can 
also inform the drug researcher on variation of PK or PD 
in early clinical studies, especially whether (1) a drug is 
exposed to the target, (2) whether the drug engages with 
the target and (3) whether the drug modulates the target in 
the desired manner. However, this aspects were not the sub-
ject of this review.
7  Conclusion and future recommendations
An interplay between many factors related both to 
drug pharmacology and a patients’ (patho)physiol-
ogy is responsible for the drug treatment outcome for 
the patient. Variability in all these processes can yield 
variability in treatment outcome. While conventional 
covariates are often sufficient in prospectively inform-
ing treating physicians on the PK of individuals, phar-
macometabolomics has proven to have additional value 
in prospectively informing PK and aiding in prospective 
drug dose individualization when conventional covariates 
cannot explain inter-individual variability sufficiently. 
Compared to pharmacogenomics, pharmacometabo-
lomics takes the actual health state into account. This is 
especially important in critically-ill patients, the elderly 
or terminal patients where many drug–drug interaction 
occurs, and also for drugs with a narrow therapeutic 
window and relatively high unexplained inter-individual 
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variability, and where you want to predict outcome before 
starting any treatment rather than using therapeutic drug 
monitoring to modify the treatment regime. This may be 
particularly relevant in patient populations taking multi-
ple drugs or which rapidly change their health state, such 
as patients with organ failure or organ transplants, but 
also in pediatric or elderly patients or pregnant women.
Pharmacometabolomics can aid in predicting pharma-
codynamics and ultimately clinical treatment outcome. 
As (patho)physiology changes during disease and phar-
macotherapy, it is important to not consider the endog-
enous metabolites as static variables in isolation. The 
influence of drug dose and temporal changes in drug con-
centrations and metabolite network interactions should be 
part of these investigations as well, before endogenous 
metabolite markers can be considered for informing drug 
selection or drug dose selection in patients. Therefore, 
both PK and PD, should be included in pharmacometabo-
lomics studies, where currently often PK is not consid-
ered in many PD pharmacometabolomis studies.
In conclusion, pharmacometabolomics is very prom-
ising for predicting pharmacokinetics and pharmacody-
namics, and if we can manage to incorporate findings in 
this field in clinical practice, we are able to realize per-
sonalized medici.
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